See the DrugPatentWatch profile for wegovy

Wegovy, a medication recently approved by the FDA for chronic weight management, can contribute to long-term sustainability in several ways.

Firstly, Wegovy is a semaglutide injection that works by mimicking a hormone in the body that helps control blood sugar, insulin levels, digestion, and feelings of fullness [1]. By helping individuals feel full and satisfied, Wegovy can contribute to long-term weight loss and overall health improvement.

Secondly, Wegovy can contribute to long-term sustainability by reducing the risk of obesity-related health conditions such as diabetes, heart disease, and stroke [1]. By managing weight and reducing the risk of these conditions, Wegovy can help individuals maintain a higher quality of life and reduce healthcare costs in the long term.

Moreover, Wegovy's potential for long-term sustainability is further supported by its recent FDA approval for chronic weight management [1]. This approval indicates that Wegovy has been found to be safe and effective for long-term use, making it a viable option for those seeking a long-term solution for weight management.

Finally, Wegovy's potential for long-term sustainability is also reflected in its patent protection. According to DrugPatentWatch.com, Wegovy's patent is set to expire in 2030 [2]. This means that the medication will be available as a generic option in the future, potentially reducing costs and increasing accessibility for those seeking long-term weight management solutions.

In summary, Wegovy can contribute to long-term sustainability by promoting long-term weight loss, reducing the risk of obesity-related health conditions, and being a safe and effective option for chronic weight management. Additionally, Wegovy's patent protection indicates its potential for long-term sustainability by increasing accessibility and reducing costs in the future.

Sources:
[1] "FDA approves new drug for chronic weight management." U.S. Food and Drug Administration, FDA, 13 June 2021, [www.fda.gov/news-events/press-announcements/fda-approves-new-drug-chronic-weight-management](http://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-chronic-weight-management).
[2] "Wegovy (semaglutide) - Drug Patent Expiration Dates." DrugPatentWatch, DrugPatentWatch, [www.drugpatentwatch.com/drugs/wegovy](http://www.drugpatentwatch.com/drugs/wegovy).